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REAPPRAISAL OF TEMPORARY LEVODOPA WITHDRAWAL ("DRUG HOLIDAY") 
IN PARKINSON'S DISEASE 
RICHARD MAYEUX, M.D., YAAKOV STERN, PH.D., KEVIN MULVEY, M.D., AND LUCIEN COTE, M.D. 
Abstract Transient withdrawal of therapy has been ad-
vocated as a method of dealing with the complications 
of long-term use of levodopa in the treatment of Parkin-
son's disease. We retrospectively examined the effect of 
a 10-day period of levodopa withdrawal, or "drug holiday," 
in 28 patients. We then compared the subsequent clini-
cal course of these patients over one year with that of 
30 other randomly selected, similar patients with Park-
inson's disease. In both groups the disease progressed; 
there was no difference in disease severity, capacity 
for daily living activities, or total amounts of dopamine 
T EMPORARY withdrawal oflevodopa, or a "drug 
holiday," may seem to be a radical way to manage 
the complications of long-term levodopa therapy in 
Parkinson's disease. However, investigators report 
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agonists eventually used. For some patients, it was pos-
sible to reduce dopamine agonists used immediately after 
the drug holiday without causing deterioration, but a 
pulmonary embolus and other complications occurred. 
Subsequent complications related to long-term dopamine-
agonist therapy during the follow-up period were similar in 
the two groups. This investigation indicates that a drug 
holiday carries some risk and does not improve the effi-
cacy of levodopa therapy or prevent the problems that oc-
cur with long-term administration. (N Engl J Med 1985; 
313:724-8.) 
fewer drug-related psychiatric complications and bet-
ter motor responsiveness when levodopa therapy is 
resumed, even at a lower dosage. 1-4 Functional im-
provement in daily activities can also last up to 
one year.5 
Nevertheless, the drug holiday is controversial. 
Some investigators have therefore advocated only 
weekend or alternate-day withdrawal of levodopa.6•7 
Benefits other than a transient improvement in psy-
chiatric complications are difficult to document, 
and the drug holiday itself may generate compli-
cations. 8 
We have retrospectively examined the records of28 
patients with Parkinson's disease who participated in 
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a 10-day drug holiday for another study. We com-
pared these data with the records of30 randomly cho-
sen patients with Parkinson's disease who continued 
to take levodopa during the same period, to evaluate 
the efficacy of complete levodopa withdrawal. 
METHODS 
Subject Selection 
The patients were drawn from a study of serotonin metobolism 
that began on April 1, 1981, and lasted until March 31, 1984. Fifty-
six consecutive patients with Parkinson's disease participated in 
that study, which included 10 days without levodopa or dopamine 
agonists. 9 In accordance with the literature, patients were told that 
these drugs would be discontinued for 10 days and that drug-related 
complications might improve, that they might require less levo-
dopa, or that they might experience an enhanced response to levo-
dopa lasting as long as a year. Forty-nine patients completed the 
first study. However, for the present study, we analyzed only the 
records of the 30 subjects examined repeatedly during the follow-up 
period by two of us (R.M. and L.C.). Two patients were later 
excluded because they had postencephalitic parkinsonism; all other 
patients had idiopathic Parkinson's disease. 
Thirty controls, regularly examined by the same two investiga-
tors, were selected from a larger group of patients with idiopathic 
Parkinson's disease who had not participated in the previous study. 
The records of these control patients were selected randomly from 
nearly 200 records of patients with Parkinson's disease by one of us 
(K.M.), who had not participated in the original study or in the care 
of any patient in the current analysis. The controls were chosen by 
an alphabetical match to the last name of each patient in the drug-
holiday group. The sole criterion was that controls had to have 
taken levodopa during the one-year period beginning at the entry 
date of the patient in the drug-holiday group to whom they were 
matched. Choices were made without knowledge of the clinical 
course during that period. The two groups were then retrospectively 
compared on measures of disease severity, the quantity oflevodopa 
or other dopamine agonists taken, independence in daily living, and 
the appearance of adverse effects of dopamine agonists. 
Drug Holiday 
The 28 patients entered the Clinical Research Center after giving 
informed consent. On the second day, all dopamine agonists were 
discontinued (including levodopa, levodopa--carbidopa, and bro-
mocriptine), but anticholinergic agents were continued, without 
any changes, in six patients who had been taking them. All patients 
received vigorous nursing care and daily physical therapy. Parkin-
sonian signs and symptoms (see below), mood, and cognition were 
assessed and rated daily. 
Quantification of Levodopa 
A levodopa-equivalence score was calculated for each dopamine 
agonist used. For levodopa--<:arbidopa, the total dose of levodopa 
per day was multiplied by four. The levodopa-equivalence score was 
determined using a ratio of 1: 10 for bromocriptine10and I: 150 for 
pergolide. 11 
Neurologlc Examination 
Twenty-two signs and symptoms of Parkinson's disease were 
ranked daily on a Parkinson's disease evaluation scale (PDE) 12 
and recorded at each measurement point. Independence in the ac-
tivities of daily living (ADL) 13 was estimated daily for patients 
during the drug holiday, and at each observation point for all 
subjects. 
Adverse Experiences 
Adverse effects included all psychiatric and motor manifestations 
not considered typical of Parkinson's disease. We included throm-
bophlebitis, hallucinations, confusion, and dyskinesias. 
Data Collection 
In both groups, the period of observation was one year. The date 
of admission was used as the point of entry or base line for the 
patients in the drug-holiday group. For control patients, a date 
between April 1, 1981, and March 31, 1983, was chosen as the base-
line entry point. 
Scores for each variable were derived at five different times for the 
drug-holiday group: at base line (the day before levodopa withdraw-
al), on Day 7 during the drug holiday, at discharge, and at 6 and 12 
months. For control patients, data from base line to subsequent 
evaluations at 6 and 12 months were used. 
All data for the drug-holiday and control groups were abstracted 
and compiled by the same blinded investigator (K.M.). He re-
viewed records of subjects to determine PDE scores, levodopa-
equivalence scores, and adverse experiences at each observation 
point. 
Statistical Analysis 
Student's I-test was used to examine differences in various group 
means; two-tailed t-tests were used exclusively. Chi-square analysis 
was used to examine any difference in the incidence of disease-
severity changes between groups. Split-plot analysis of variance 
with repeated measures 14 was used to analyze longitudinal aspects 
of the study. The mean levodopa-equivalence, ADL, and PDE 
scores for the two groups were compared at base line, six months, 
and one year, yielding group, time, and interaction effects. 
RESULTS 
Subjects 
The mean age(± S.D.) of the drug-holiday group 
was 66.5±9.3 years. The average duration of illness 
was 10.4±8.5 years, and the duration of levodopa 
therapy was 5.8±3.8 years. The 30 control patients 
had a mean age of 65.0±8.9 years, with a disease du-
ration of8.3±4.8 years; the duration oflevodopa ther-
apy was 6.5±3.9 years. The mean time before the ini-
tiation oflevodopa therapy in the drug-holiday group 
was 3. l ±5.4 years, whereas in the control group it was 
1.8±2. l years. This difference was not significant, nor 
were the differences in age at the onset of Parkinson's 
disease and duration of parkinsonism or levodopa 
therapy. Fourteen men and 14 women were in the 
drug-holiday group; 19 men and l l women were in the 
control group. 
Drug Holiday 
The PDE scores indicated much more severe dis-
ability during the period oflevodopa withdrawal, and 
ADL scores dropped precipitously. The amount of 
levodopa taken at the time of discharge from the hos-
pital, based on the levodopa-equivalence score, was 
reduced by about 50 per cent. PDE scores and ADL 
ratings at the time of discharge were similar to those at 
base line (Table l). 
Longitudinal Studies 
PDE 
The severity of parkinsonism increased for both 
groups over the year of observation (F = 12.06, 
P<0.01). The severity at base line was similar in the 
two groups, and an analysis of variance revealed no 
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Table 1. Progression of Parkinson's Disease in Patients on a "Drug Holiday" and Controls.• 
DISEASE PROGRESSION BASE LINE DRUG WITHDRAWAL DISCHARGE 6 MONTHS 12 MONTHS 
mean ±S.D. 
PDE score 
Drug-holiday group (n = 28) 
Controls (n = 30) 
35.9± 16.2 
36.6± 16.2 




ADL score (%) 
Drug-holiday group (n = 28) 
Controls (n = 30) 
69±13 
67±21 
*PDE denotes Parkinson's disease evaluation, and ADL activities of daily living. 
60±15 
difference between the groups at six months or one 
year (Table 1). 
AOL 
Independence in daily living also deteriorated 
significantly for both groups over time (F = 6.4, 
P<0.01). ADL scores, which were comparable in the 
two groups at base line, were also similar at six 
months and one year (Table l). 
Levodopa Equivalence 
Patients in the drug-holiday group took smaller 
amounts oflevodopa and other dopamine agonists im-
mediately after the period oflevodopa withdrawal, but 
levodopa-equivalence scores were comparable in the 
two groups at base line and at 6 and 12 months (Ta-
ble 2). The amount of anticholinergic agents used was 
the same in the two groups. 
Change in Severity 
The frequency of change in the severity of disease 
over time was also examined. We arbitrarily chose a 
change of five points in the base-line PDE score as 
indicative of increased severity (increased score) or 
decreased severity (decreased score). In the drug-holi-
day group, severity increased in nine patients and de-
creased in seven; severity remained unchanged in the 
others. Among controls, severity increased in 12, de-
creased in 4, and was unchanged in the others. Chi-
square analysis revealed no statistically significant dif-
ference in the incidence of these changes between 
groups. If only the patients who experienced a change 
in severity are considered, the calculated odds ratio is 
2.3 in favor of the drug holiday. Although this differ-
ence is not statistically significant, it is possible that in 
a larger study a clearer benefit might have been ob-





tN = 26. 
bitrary" criterion (a change of five points in the PDE 
score); the actual PDE comparisons revealed no sig-
nificant differences between the groups. One patient 
in the drug-holiday group died from a myocardial in-
farction before the last examination, and another had 
a stroke; both were excluded from this analysis. 
Adverse Experiences 
Drug Holiday 
Two patients became so rigid that parenteral nutri-
tion was required. Other medical complications were 
observed; one patient had a pulmonary embolus, two 
experienced severe rigidity, another had a urinary 
tract infection, one became hypotensive, one had tran-
sient psychosis, one had dystonic leg cramps, and one 
experienced repeated falls. No similar medical compli-
cations were noted in the records of the controls at any 
point in the study period. 
Follow-up Period 
During the year of follow-up, the distribution of 
drug-related dyskinesias, psychiatric symptoms, and 
fluctuations were comparable in the two patient groups 
in terms of frequency and severity (Table 3). Howev-
er, adverse experiences over the study period (includ-
ing the time oflevodopa withdrawal) were significant-
ly more frequent in the drug-holiday group (P<0.01; 
odds ratio, 3.75). 
D1scuss10N 
Our results do not support the claim that levodopa 
withdrawal, or a drug holiday, has a long-term benefit 
in the management of Parkinson's disease. Patients 
left the hospital taking less levodopa after the drug 
holiday, but the reduction in dose usually lasted less 
than six months. Psychiatric symptoms were similar 
Table 2. Levodopa-Equivalence Scores.• 
GROUP BASE LINE DRUG WITHDRAWAL DISCHARGE 6 MONTHS 12 MONTHS 
Drug-holiday group (n = 28) 
Controls (n = 30) 








tN = 26. 
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before and after the drug holiday, and hallucinations 
developed in two patients within six months after levo-
dopa withdrawal. Subsequent dyskinesias and clinical 
fluctuations ("wearing off") were comparable in the 
two groups, and the disease progressed similarly in 
both despite the drug holiday. 
Long-term levodopa therapy alters dopamine-re-
ceptor sensitivity, 15, 16 and withdrawal of levodopa 
may alleviate that phenomenon. A drug holiday pre-
sumably allows resensitization of the striatal dopa-
mine receptors,2' 15•16 improving the response to exoge-
nous levodopa. The lack of a long-term benefit may 
indicate that the period of drug withdrawal is too 
brief. However, the discomfort and risks of serious 
complications probably preclude the continuation of a 
drug holiday for more than l 0 days. 
Adverse experiences have been encountered by oth-
er investigators, and despite skilled, aggressive nurs-
ing care, they occurred during the period of levodopa 
withdrawal in the patients we studied. The lack of 
group differences in the frequency of adverse experi-
ences during follow-up also indicates that levodopa 
withdrawal has no prophylactic benefit. 
Our patients were not selected for the presence of 
complications from levodopa, but the prevalence of 
such complications in the drug-holiday group was 
comparable to that reported in previous studies. 2-5 
Other studies of a drug holiday in Parkinson's disease 
have been small and have lacked controls. 1-5 Some 
studies were also retrospective, but did not report 
the method of patient selection or data analysis or 
the period of follow-up. 2•3•5 In one study all but 
one subject was demented. 3 Koller et al.5 followed 
14 patients for up to a year and reported increased 
motor responsiveness and reduced side effects of levo-
dopa. However, the only method of data analysis was 
Student's t-test, which is inappropriate for repeat-
ed observations over time, 17 and controls were not 
studied. 
Kofman8 reported that 9 of 24 patients remained 
improved for one year after a drug holiday, and 6 of 
them remained better even longer. Improved motor 
function was observed, but there were no long-term 
benefits with regard to fluctuations or drug-induced 
psychosis. All patients were "helpless" during the 
period of levodopa withdrawal, and intensive nurs-
ing care was required. Rigidity was frequently se-
vere, and thrombophlebitis developed in one pa-
tient. Kofman concluded that a drug holiday was 
of limited value because of the enormous risk and 
small benefit. 
Studies without controls, such as the previous inves-
tigations of a drug I:ioliday,2-3 can be clinically useful 
when promising results of a new treatment are report-
ed or when successful modifications in an accepted 
treatment are recognized, but the data are not neces-
sarily universal. 18 Although the attempt to use a drug 
holiday may have originally been justified by the lack 
of alternative treatments, our critical examination 
Table 3. Adverse Experiences during the Follow-up Period. 
BASE LINE 6 MONTHS 12 MONTHS 
no. of patients 
Dyskinesias 
Drug-holiday group 5 6 5 
Controls II 10 12 
Fluctuations 
Drug-holiday group 3 3 3 
Controls 4 2 2 
Psychosis 
Drug-holiday group I 3 3 
Controls 0 0 3 
with a control group suggests a different conclusion. 
Complete withdrawal of levodopa only briefly re-
duces subsequent requirements for the drug, does not 
reduce the incidence or severity of complications asso-
ciated with long-term levodopa therapy, and does not 
alter the subsequent clinical course. It may transiently 
relieve drug-related probems, such as hallucinations, 
but does not prevent the later onset of dyskinesias, 
fluctuations, or psychosis when therapy is resumed. 
Use of a lower dose oflevodopa after the drug holiday 
may suggest an overdose before drug withdrawal rath-
er than an enhanced response afterward. 
There is little doubt that complications occur with 
long-term levodopa therapy. A transient reduction 
in the dose may be effective in eliminating some 
side effects. However, a drug holiday does not en-
hance the efficacy or prevent the problems of long-
term levodopa therapy, and it may engender serious 
risks. 
We are indebted to the nursing staff of the Clinical Research 
Center and Heather Conklin, R.N., who made this study possible; 
to Mr. Donald McMahon for his assistance in data management; 
and to Lewis P. Rowland, M.D., for his help on this manuscript. 
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SPECIAL ARTICLE 
POTENTIAL EPIDEMIC OF CREUTZFELDT-JAKOB DISEASE FROM HUMAN GROWTH 
HORMONE THERAPY 
PAUL BROWN, M.D., D. CARLETON GAJDUSEK, M.D., C.J. GIBBS, JR., Ptt.D., AND DAVID M. ASHER, M.D. 
A DECADE after the demonstration that Creutz-feldt-Jakob disease could be accidentally trans-
mitted from one person to another during brain or eye 
surgery, 1•2 iatrogenic Creutzfeldt-Jakob disease has 
reappeared as a result of earlier therapy with human 
growth hormone, with the ominous possibility of a 
burgeoning epidemic. 
Within just a few months, three young adults in the 
United States have died from the disease, confirmed 
neuropathologically in two patients and clinically de-
tected but unconfirmed in one3; an additional neuro-
pathologically confirmed case has been identified in 
Great Britain.4 Salient data on these four cases are 
summarized in Table 1. (The details of both con-
firmed American cases5 '6 are reported in this issue of 
the Journal.) 
Four other young adult U.S. growth hormone re-
cipients who later died of chronic neurologic diseases 
that were not clinically characteristic of Creutzfeldt-
Jakob disease are also under investigation. Their ante-
mortem diagnoses were postradiation encephalopathy 
(two patients), atypical motor neuron disease (one), 
and atypical multiple sclerosis (one). 
Creutzfeldt-Jakob disease has a worldwide yearly 
incidence of about one case per million population in 
countries where physicians are fully aware of the diag-
nosis and where it has been vigorously sought. 7•8 
However, only 9 previous cases in patients under 30 
years of age9 •10 are known among more than 3000 
worldwide cases either reported in the literature or 
referred to us for experimental transmission studies, 
and 3 of these cases were iatrogenic. 1•2 The age-specif-
ic mortality rate for Creutzfeldt-Jakob disease in the 
population under 40 years of age is only 0.01 case per 
million (Brown P, et al.: unpublished data). Since ap-
proximately 10,000 Americans, all under 40, have re-
ceived human growth hormone, the expected inci-
dence of Creutzfeldt-Jakob disease in this group is 
0.0001 case per year - i.e., the chance of one case 
From the Laboratory of CNS Studies, National Institute of Neurological and 
Communicative Disorders and Stroke, National Institutes of Health. Address 
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occurring in a given year is 1 in 104• The chance of 
three cases occurring in one year is 1 in 1012, and the 
chance of six cases occurring in one year is 1 in 1024. 
Thus, the abrupt appearance of at least three cases of 
the disease in Americans under the age of 40 who had 
all been treated with growth hormone derived from 
pools of human pituitary glands obtained at autopsy 
strongly incriminates Creutzfeldt-Jakob disease-con-
taminated growth hormone as the cause. 
A potential conflict exists between the legitimate 
interests of patients, parents, and physicians, many of 
whom are willing to accept a small risk of iatrogenic 
Creutzfeldt-Jakob disease rather than relinquish the 
benefit of therapy with human growth hormone; phar-
maceutical firms that make the hormone, which wish 
both to exonerate their products and continue to mar-
ket them; and public health officials and scientists, 
who must decide what degree ofrisk attends treatment 
with human growth hormone and formulate a policy 
that minimizes this risk yet does not ignore the hor-
monal needs of patients. 
From the available data, and allowing for the influ-
ence of variables that are less well defined, one 
can estimate the risk of inadvertent contamination 
of human growth hormone by Creutzfeldt-Jakob dis-
ease virus. The U.S. annual mortality rate from all 
causes during the 1960-1980 period was approximate-
ly 0.9 per cent, or, in the population of 250 million, 
somewhat fewer than 2.5 million deaths each year. 
Since the annual mortality rate from Creutzfeldt-
Jakob disease is approximately 0. 7 to 1.0 per mil-
lion, or, in the U.S. population, somewhat fewer than 
250 deaths per year, it follows that roughly 1 in 10,000 
deaths in this country is due to this disease. Because 
lots of pituitaries used in the preparation of human 
growth hormone have varied from 500 to nearly 
20,000 glands, frequent episodes of contamination can 
be expected to have occurred, unless patients with 
Creutzfeldt-Jakob disease were systematically ex-
cluded as sources of pituitary glands. Such exclusion 
was unlikely for at least two reasons: ( 1) patients with 
chronic neurologic diseases were not banned from col-
lection, and until the mid-l 970s diagnostic awareness 
